The initiation of the ACC Ambulatory Surgical Center Registry comes at a time when hospitals are expanding their structural heart programs. The registry is providing valuable details about which patients should stay at the hospital and which can be treated in an outpatient setting.
Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains the political and patient care issues involved with ending Affordable Care Act subsidies.
Heart teams continue to play a major role at hospitals and health systems all over the world. Cardiac imagers who have trained in multiple modalities can provide those teams with a significant amount of value.
CEO Dana Smetherman, MD, MPH, MBA, explains American College of Radiology efforts to help members understand and enable easier integration of artificial intelligence.
Wael Jaber, MD, chair of the 2025 American Society of Nuclear Cardiology annual meeting, shared some key takeaways from the conference. “This is no longer just about imaging for coronary disease," he explained. "Nuclear cardiology now helps guide therapy across a wide range of conditions."
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, said tricuspid valve treatments are a popular topic among cardiologists right now. TAVR research, meanwhile, remains as important as ever.
The Medical Group Management Association (MGMA) Senior Vice of Government Affairs, Anders Gilberg, explains MGMA’s 28-page letter to CMS on issues with the proposed 2025 Medicare Physician Fee Schedule.
Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.
Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
